Development and Validation of an Extracellular Matrix Gene Expression Signature for Prognostic Prediction in Patients with Uveal Melanoma
Authors:
- Alejandro Mejía-GarcíaAMAlejandro Mejía-García
- Carlos A. OrozcoCOCarlos A. Orozco
- Julius HerzogJHJulius Herzog
- Oscar Alarcón-BetancourthOAOscar Alarcón-Betancourth
- Alexandra Meneses-TorresAMAlexandra Meneses-Torres
- Marcela RamírezMRMarcela Ramírez
- Johanna GonzálezJGJohanna González
- Yina ZambranoYZYina Zambrano
- Alba Lucia CombitaACAlba Lucia Combita
- Diego A. BonillaDiego A. Bonilla
- Seth FrietzeSeth Frietze
Open Access
- 1 May 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (9) , 4317
Abstract
Uveal melanoma (UVM) is an aggressive cancer with a poor prognosis, particularly in metastatic cases. This study aimed to develop and validate a novel extracellular matrix (ECM) gene expression signature to predict prognosis and stratify patients by risk. ECM-related genes were identified and used to construct a prognostic model through Lasso–Cox regression analysis, leveraging RNA sequencing data from 80 UVM patients in The Cancer Genome Atlas (TCGA). The model was validated using an independent cohort of 63 UVM patients. Survival analyses, immune infiltration profiling, and functional enrichment analyses were conducted to evaluate the biological significance and clinical utility of the signature. The ECM signature stratified patients into high- and low-risk groups with significant differences in survival outcomes. High-risk patients showed elevated expression of MMP1 and MMP12, which are associated with ECM remodeling and immune modulation, alongside increased infiltration of immunosuppressive cells, such as M2 macrophages. Validation confirmed the prognostic value of the signature across cohorts. Functional analyses highlighted the involvement of ECM-related pathways, epithelial–mesenchymal transition, and immune system interactions in tumor progression. This ECM gene expression signature is a robust prognostic tool for UVM, offering insights into tumor biology and immune microenvironment interactions. It holds promise for improving patient stratification and guiding personalized therapeutic strategies. Further research is warranted to explore the functional roles of these genes in UVM progression.Keywords
This publication has 86 references indexed in Scilit:
- TIMP1 is an early biomarker for detection and prognosis of lung cancerClinical and Translational Medicine, 2023
- Single cell RNA‐sequencing: A powerful yet still challenging technology to study cellular heterogeneityBioEssays, 2022
- EEF2K silencing inhibits tumour progression through repressing SPP1 and synergises with BET inhibitors in melanomaClinical and Translational Medicine, 2022
- Extracellular Matrix Remodeling and Development of CancerStem Cell Reviews and Reports, 2020
- RETRACTED ARTICLE: MMP1 3′UTR facilitates the proliferation and migration of human oral squamous cell carcinoma by sponging miR-188-5p to up-regulate SOX4 and CDK4Molecular and Cellular Biochemistry, 2020
- Association of Partial Chromosome 3 Deletion in Uveal Melanomas With Metastasis-Free SurvivalJAMA Ophthalmology, 2020
- Upregulation of the adipokine genes ADIPOR1 and SPP1 is related to poor survival outcomes in colorectal cancerJournal of Surgical Oncology, 2018
- Fibroblasts potentiate melanoma cells in vitro invasiveness induced by UV-irradiated keratinocytesHistochemistry and Cell Biology, 2018
- MMP-12, a Promising Therapeutic Target for Neurological DiseasesMolecular Neurobiology, 2017
- Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survivalJournal of Neuro-Oncology, 2009